The Record
The skin visual record
A photograph helps this site only when a reader can say what it shows, who published it, and what it is not allowed to prove. The entries below are that list. The pixels of identifiable patients stay with the journals.
Last reviewed November 15, 2026.
What a pair has to carry
- The same person, the same site, and two dates.
- Lighting and distance close enough that a darker pixel is the skin, not the room.
- A citation, a license note, and one sentence on the claim the picture supports.
- For a mole: whether anyone biopsied it, and what the slide said.
A forum “after” with no interval and a product name in the caption fails every line. Those images are not collected.
Mole change
More than a hundred new moles after a short course
A phototype II man in his twenties developed more than 100 melanocytic nevi, mostly on the back, within weeks of a four-week course sold as Melanotan II. Ten of the most atypical were removed; histopathology was dysplastic nevi, three with severe dysplasia. A pigmented basal-cell carcinoma on the shoulder was also removed.
Not a claim. The report does not prove the compound caused a melanoma, and it is not a result to copy. It does not state a dose anyone should use.
Clinical and dermatoscopic figures remain on the journal site. They are not republished here.
Eruptive naevi after an injection sold as melanotan
Cousen, Colver, and Helbling reported eruptive melanocytic naevi after injection of an unlicensed peptide sold as melanotan, in a young woman who also used tanning beds. The letter sits in the same cluster as Langan’s earlier report of rapidly changing moles.
Not a claim. A case letter is an alarm, not a rate. It does not rank products and it does not clear any individual new mole.
The letter’s figures stay with the British Journal of Dermatology.
The same skin, many moles
New and old moles, checked against a photograph from the year before
A 40-year-old man with a prior melanoma and atypical nevi grew new pigmented nevi and watched existing ones darken and look more irregular within weeks of injecting a product sold as Melanotan II. The change was confirmed against clinic photographs from a year earlier. After he stopped, the nevi lightened over the following months and the growth features faded. Two biopsies were dysplastic nevi.
Not a claim. A before-and-after of the trunk is a surveillance document, not a tan. The paper’s conclusion is that synthetic α-MSH peptides can drive neoplastic melanocytes in a predisposed patient. Causation of a new melanoma is not established by this case.
The comparison photographs and dermatoscopic images stay at JAMA Dermatology.
Pigment without a beach
Addisonian darkening: the high state, with no vial
In primary adrenal insufficiency, excess ACTH activates MC1R. Skin darkens in creases, scars, gums, and sun-exposed sites. Physicians have used a new photograph that no longer matches the old one as a clue. The darkening is melanocortin drive and it is a disease.
Not a claim. It is not evidence that a cosmetic agonist is “what the body already does,” and it is not a tanning result. This page does not advise on treating adrenal failure.
Standard clinical descriptions of Addisonian pigmentation. No single patient photograph is adopted as the site’s figure.
Teaching photographs of identifiable patients are not hosted. The page draws the sites, not a person.
Approved-drug endpoints
Afamelanotide in erythropoietic protoporphyria: hours of light, not a tan
The randomized trials of the approved implant measured time spent outdoors without pain from visible light, in people with a rare phototoxic disease. A positive result is a photoprotection endpoint in that disease.
Not a claim. It is not a cosmetic before-and-after, and it is not evidence about Melanotan II. Any trial photograph, if one is published, answers the disease question only.
Trial figures stay with the New England Journal of Medicine.
CUV105 vitiligo readout: the slot is empty until the paper exists
When the sponsor publishes the Phase III figures, the only claim this record will store is repigmentation of vitiligo on the trial’s own scores (T-VASI50, F-VASI75), in diagnosed patients, Fitzpatrick types specified by the protocol.
Not a claim. A repigmentation photograph is not photoprotection and not a cosmetic tan. Nothing is entered here in advance of the paper.
Clinuvel CUV105, topline expected December 2026. No citable figure yet. See the regulatory tracker.
No image is reserved, downloaded, or described as a result before publication.
Fitzpatrick reference
The Fitzpatrick figure above is the reference. It is original to this page. It is not a before-and-after, and it is not a photograph.
Left out on purpose
Influencer before-and-afters, forum progress threads, nasal-spray diaries, and any pair that implies a dose, a schedule, or a seller. Lighting is uncontrolled, the interval is whatever the caption says, and on this domain those pictures would work as advertising. The rule is journalism about the gray market, never a guide to it.
The mole entries are the ones that change a clinical argument. Read them next to The mole problem. A new or changing mole is a reason to see a dermatologist, not a reason to compare yourself with a case report.